Shots:

• The P-III trial evaluates the efficacy & safety of a 3-day course of Veklury (IV) vs PBO in a ratio (1:1) in 562 non-hospitalized patients ≥aged 12yrs. with COVID-19 who are at high risk for disease progression. The results will be presented at IDWeek 2021
• The results showed an 87% & 81% reduction in risk for composite 1EPs & 2EPs of COVID-19 related hospitalization or all-cause death @28Day (0.7% vs 5.3%) & (1.6% vs 8.3%)- no new safety signals & no deaths were observed
• Veklury is a nucleotide analog with broad-spectrum antiviral activity both in vitro/ in vivo in animal models against multiple emerging viral pathogens. The company plans to file an IND with the FDA in early 2022

  Ref: Gilead | Image: Gilead